CPT code 0171U: Genomic panel, 23-gene blood cancer panel2026 Medicare lab fee · Clinical Laboratory Fee Schedule
Targeted 23-gene DNA analysis for AML, MDS, and MPN evaluates sequence variants, rearrangements, and minimal residual disease, with findings reported as present or absent.
Medicare pays $1,519.06 for 0171U under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.
Medicare lab fee · CLFS 2026 Q4
National CLFS amount
$1,519.06
In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.
- Geographic adjustment
- None
- Office vs facility
- Same
- Since 2022
- Unchanged
- CMS updates
- Quarterly
Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 7 sections
What 0171U covers
This proprietary laboratory analysis examines targeted DNA sequences across 23 genes associated with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). It assesses sequence variants, rearrangements, and minimal residual disease, with findings reported as present or absent. The result presents the targeted findings in a presence-or-absence format.
Report 0171U once for the defined 23-gene panel; the gene count does not create separate units. Medicare pays the test only under the Clinical Laboratory Fee Schedule (CLFS), with one national amount across localities and no geographic or office-versus-facility adjustment. The 2026 national CLFS amount is $1,519.06, unchanged from 2022 through 2026. No physician fee schedule payment applies to this code.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 0171U
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
One national amount
CMS sets a single Clinical Laboratory Fee Schedule amount for 0171U. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Not on the physician fee schedule
The physician fee schedule doesn’t list 0171U: Medicare pays the test only from the CLFS.
0171U on the lab fee schedule since 2020
0171U · CLFS 2026 Q4 (current)
$1,519.06
Unchanged since Jan 1, 2022
Every change on file
- Jan 1, 2022 · CLFS 2022 Q1MAC-priced → $1,519.06
26 quarterly CLFS releases on file, first CLFS 2020 Q3. A code missing from a quarter wasn’t on that release.
0171U compared with similar tests
- 0172UTumor gene assayBRCA1/2 and genomic instability$3,030.00
- 0172U is a solid-tumor analysis focused on BRCA1 and BRCA2. Use 0171U for the defined 23-gene AML, MDS, and MPN panel.
- 0174UTumor protein assay30 targets by mass spectrometry$1,305.37
- 0174U describes a solid-tumor analysis involving 30 protein targets. 0171U is a DNA panel for AML, MDS, and MPN that assesses variants, rearrangements, and minimal residual disease.
0171U billing questions
When is 0171U appropriate?
Use it for the specified targeted DNA analysis covering AML, MDS, and MPN, including evaluation of sequence variants, rearrangements, and minimal residual disease.
Are the 23 genes reported as separate units?
No. The 23-gene count describes the panel; it is not a separate unit for each gene.
Does Medicare pay a separate physician interpretation for 0171U?
0171U is paid only under the CLFS; no physician fee schedule payment applies to this code.
Does the CLFS amount vary by location or setting?
No. Medicare uses one national amount for the code across localities, without an office-versus-facility adjustment.
How does 0171U differ from a BRCA1/BRCA2 tumor analysis?
0171U is the 23-gene panel for AML, MDS, and MPN. Code 0172U describes a solid-tumor analysis focused on BRCA1 and BRCA2.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets · Coming soon
Put 0171U and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist